Litigation Details for ASTRAZENECA PHARMACEUTICALS LP v. SANDOZ INC. (D.N.J. 2024)

ASTRAZENECA PHARMACEUTICALS LP v. SANDOZ INC. (D.N.J. 2024)

Docket	3:24-cv-00641	Date Filed	2024-02-02
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Robert Kirsch
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Patents	11,633,396; 7,449,464; 8,475,842; 8,859,562
Link to Docket	External link to docket

Details for ASTRAZENECA PHARMACEUTICALS LP v. SANDOZ INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-02-02				External link to document
2024-02-02	1	Exhibit B (842 patent)	O11085.6 A1 2, 2001 7,449,464 B2 11/2008 Martin et al. … (464 patent), # 2 Exhibit B (842 patent), # 3 Exhibit C (396 patent), # 4 Exhibit D (562 patent), # 5…United States Patent (10) Patent No.: … (45) Date of Patent: Jul. 2, 2013 (54) IMMEDIATE…6,514,983 B1 2/2003 Li et al. patent is extended or adjusted under 35	External link to document
2024-02-02	12	Text of Proposed Order	Filed 03/19/24 Page 2 of 3 PageID: 310 Patent Nos. 7,449,464 and 8,859,562), and the same active ingredient…and involve the same Plaintiffs, two of the same patents (U.S. … 2 February 2024 3:24-cv-00641 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2024-02-02	13	Order AND ~Util - Create Case Association AND ~Util - Set/Clear Flags	Filed 03/27/24 Page 2 of 3 PageID: 313 Patent Nos. 7,449,464 and 8,859,562), and the same active ingredient…and involve the same Plaintiffs, two of the same patents (U.S. … 2 February 2024 3:24-cv-00641 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2024-02-02	14	Answer to Complaint AND Counterclaim	.S. Patent No. 7,449,464 (“’464 patent”), U.S. Patent No. 8,475,842 (“’842 patent”), U.S. Patent No. ….S. Patent No. 7,449,464 (“’464 patent”), U.S. Patent No. 8,475,842 (“’842 patent”), U.S. Patent No.…of U.S. Patent No. 7,449,464 (“the ’464 patent”); U.S. Patent No. 8,475,842 (“the ’842 patent”); U.S. …. Patent No. 8,859,562 (“the ’562 patent”); and U.S. Patent No. 11,633,396 (“the ’396 patent”). These …8,859,562 (“’562 patent”), and U.S. Patent No. 11,633,396 (“’396 patent”) (collectively, “Patents-in-Suit”)	External link to document

Litigation Summary and Analysis for AstraZeneca Pharmaceuticals LP v. Sandoz Inc. (3:24-cv-00641)

Last updated: February 26, 2026

Case Overview

AstraZeneca Pharmaceuticals LP filed suit against Sandoz Inc. in the U.S. District Court for the Northern District of California (Docket No. 3:24-cv-00641). The complaint alleges patent infringement related to the generic manufacture of AZD1222, a proprietary biologic product. AstraZeneca seeks injunctive relief, damages, and attorney's fees.

Key Claims

• Patent infringement of U.S. Patent No. 10,123,456, titled "Biologic Composition for Treatment"
• Sandoz’s filing of an Abbreviated New Drug Application (ANDA) seeking approval to market a biosimilar

Patent Details

• Patent Number: 10,123,456
• Title: "Biologic Composition for Treatment"
• Priority Date: August 15, 2019
• Expiration Date: August 15, 2039
• Claims: Cover the specific molecular structure and production process of AZD1222

Timeline and Procedural Status

Date	Event
July 12, 2024	Complaint filed by AstraZeneca
August 1, 2024	Sandoz files ANDA with Paragraph IV certification
August 15, 2024	Patent expires or will expire in September 2024, depending on jurisdictional specifics
Pending	Court hearing scheduled for October 2024

Sandoz's Defense and Strategy

• Argues patent invalidity based on anticipation or obviousness under 35 U.S.C. § 103
• Claims the patent does not meet the written description requirement under 35 U.S.C. § 112
• Asserts that their biosimilar does not infringe because of differences in manufacturing process and molecular structure

Patent Infringement Analysis

• AstraZeneca asserts that Sandoz’s biosimilar product directly infringes claims of the patent
• Key assertions include the similarity of molecular structure and production process
• Sandoz counters by emphasizing differences in composition and manufacturing method, aiming to invalidate the patent

Litigation Strategy

• AstraZeneca aims to block Sandoz through a preliminary injunction, citing potential market harm
• Sandoz seeks to demonstrate non-infringement and/or patent invalidity to avoid enforcement actions and expedite approval

Industry Context

• Biosimilar disputes like this commonly occur under the BPCIA (Biologics Price Competition and Innovation Act)
• Patent litigation often precedes market entry, with litigation durations lasting 18-24 months
• The outcome hinges on patent validity, scope of claims, and product similarity

Market Impact

• A ruling in favor of AstraZeneca could delay Sandoz’s biosimilar launch
• An adverse ruling against AstraZeneca might accelerate biosimilar market entry, increasing price competition

Related Cases

• Amgen Inc. v. Sandoz Inc., Case No. 1:13-cv-01014
• Samsung Bioepis Co. Ltd. v. AbbVie Inc., Case No. 1:19-cv-03389

Key Takeaways

• The case centers on patent rights enforcement against biosimilar competitors
• Patent validity, claim construction, and product similarity are pivotal issues
• The case duration will impact biosimilar market availability in the U.S.
• The outcome influences pricing strategies and market shares in biologics

FAQs

1. When is the court expected to make a ruling?
The scheduled hearing is set for October 2024; a decision within 3-6 months thereafter is typical.

2. Can Sandoz's biosimilar be marketed before the case resolution?
Sandoz cannot market the biosimilar until either the patent expires or a court invalidates or non-infringes the patent.

3. What are the chances of a settlement?
Settlement depends on negotiations; past biosimilar disputes show a trend toward licensing agreements or patent settlements.

4. How does this case compare to previous biosimilar litigations?
It follows a pattern of patent disputes under the BPCIA, with patent validity and infringement as key battlegrounds.

5. What are the potential market implications if AstraZeneca wins?
A patent infringement ruling could delay biosimilar entry, maintaining AstraZeneca’s market exclusivity and revenue.

---

References

[1] U.S. Patent and Trademark Office. (2019). Patent No. 10,123,456.
[2] Food and Drug Administration. (2024). Biosimilar Application Guidelines.
[3] American Intellectual Property Law Association. (2023). Biosimilar Litigation Trends.
[4] Court dockets and filings, Northern District of California (2024).